Elevated Chemical Level Spurs Tylenol Cold Medicine Recall

Posted on August 16, 2011

Johnson & Johnson announced Monday that it is recalling over two million packages of over-the-counter Tylenol brand cold medicine due to an excessive amount of a chemical compound found in the drug, report news sources

Subject to recall are almost 2.5 million packages of Tylenol Cold Multi-Symptom Nighttime Rapid Release Gelcaps. The cold relief medicine is being pulled from both retail shelves and wholesaler stock because of the discovery in some capsules of slightly higher-than-expected levels of chlorpheniramine ammonio acetate (CPAA). The health care giant says the recall does affect any drug that consumers may already have in their homes.

CPAA, formed by combining two product ingredients, has not been associated with any health complaints.

The recalled medicine was produced at production facilities operated by beleaguered McNeil Consumer Healthcare, which has been at the heart of several J&J drug recalls, including actions involving Tylenol brand products, Benadryl and Sudafed brand products, and prescription drugs Risperdal and Prezista. Product recalls have cost J&J about $900 million in sales over the last year.

I hope this latest J&J recall does not negatively impact consumers.

As a Los Angeles personal injury lawyer, I encourage consumers to stay safe by practicing good medicine cabinet maintenance habits like clearing out expired medicines and prescriptions and staying aware of potential negative drug interactions.

How Can We Help You?

If you have a legal matter you would like to discuss with an attorney from our firm, please call us at (310) 477-1700 or complete and submit the e-mail form below, and we will get back to you.

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.

*Required Fields